today announced that the first patient has been dosed in its Phase 1b clinical In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema ...

Descemet stripping only (DSO) offers a novel approach to FECD management, avoiding donor tissue complications and promoting endothelial restoration. Rho kinase inhibitors, such as ripasudil, may ...

2024). Furthermore, the synergistic effects of these drugs on lowering glomerular pressure and proteinuria offer a novel approach to DKD management. Residing on the cell surface of the corneal ...

It was suggested that the lack of complete success was due to the failure of the glycerol–saline technique to protect the corneal endothelium. It was therefore decided to investigate directly ...

AURN001 is a combination cell therapy product candidate comprised of allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632). AURN001 is intended to be ...

The study enrolled 97 people in the U.S. and Canada with corneal edema secondary to endothelial dysfunction, a disease that can currently only be treated with invasive specialty surgery.

an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction. According to the company, AURN001 combines allogeneic human corneal ...

In a 2021 study published in the Journal of Cornea and External Disease, 12 out of 40 keratopigmentation patients experienced light sensitivity in the first month. Five said the pigment faded or ...